Ventilator-associated pneumonia

info-atbvac > Ventilator-associated pneumonia

Except for ICU patients, ceftolozane-tazobactam is a treatment option for multi-drug resistant P. aeruginosa. ( Jorgensen SCJ. et al )

Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections.

28 avr | Dr Olivier Leroy

Gram-negative bacilli and especially P. aeruginosa are responsible for increasingly multi-drug resistance challenging problems. The association between a new cephalosporin … Suite

In units with high rates of resistance empirical use of colistin in the treatment of late ventilator-associated pneumonia cannot be recommended. ( Cisneros JM. et al. )

Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial.

27 fév | Dr Olivier Leroy

Multidrug-resistant gram-negative bacilli (MDR-GNB), including Pseudomonas aeruginosa, Acinetobacter baumannii, and extended-spectrum beta-lactamase (ESBL)-producing or carbapenemase-producing Enterobacteriaceae, are currently the pathogens … Suite

Acyclovir may improve the prognosis of patients with an elevated HSV viral load during ventilator-associated pneumonia not responding to antibiotic treatment. ( Schuierer L. et al. )

Impact of acyclovir use on survival of patients with ventilator-associated pneumonia and high load herpes simplex virus replication.

18 fév | Dr Olivier Leroy

Herpes simplex virus (HSV) replication can be detected in the respiratory secretions of a high proportion of ventilated intensive care … Suite